

# Joshua T Kantrowitz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7720745/joshua-t-kantrowitz-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74  
papers

2,651  
citations

27  
h-index

50  
g-index

91  
ext. papers

3,253  
ext. citations

5.6  
avg, IF

5.55  
L-index

#	Paper	IF	Citations
74	Improving reproducibility of proton MRS brain thermometry: theoretical and empirical approaches.. <i>NMR in Biomedicine</i> , <b>2022</b> , e4749	4.4	
73	Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions. <i>CNS Drugs</i> , <b>2021</b> , 35, 1153-1161	6.7	0
72	How do we address treating the negative symptoms of schizophrenia pharmacologically?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1811-1813	4	3
71	Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 653026	5	5
70	Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 419	8.6	5
69	Additional perspective on cariprazine and negative symptoms. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 1-2	4	2
68	D-Serine: A Cross Species Review of Safety. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 726365	5	1
67	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglmetad and TS-134 on ketamine-induced psychotic symptoms and pharmacBOLD in healthy volunteers. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 1842-1850	8.7	15
66	Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 1339-1345	8.7	16
65	Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study. <i>Schizophrenia Research</i> , <b>2020</b> , 218, 321-323	3.6	1
64	Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia. <i>Journal of Psychiatry and Brain Science</i> , <b>2020</b> , 5,	1.7	1
63	New discoveries for an old drug: a review of recent olanzapine research. <i>Postgraduate Medicine</i> , <b>2020</b> , 132, 80-90	3.7	20
62	Targeting Serotonin 5-HT Receptors to Better Treat Schizophrenia: Rationale and Current Approaches. <i>CNS Drugs</i> , <b>2020</b> , 34, 947-959	6.7	9
61	Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 629144	5	3
60	Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 221	8.6	11
59	Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. <i>Psychiatry Research</i> , <b>2019</b> , 275, 78-85	9.9	12
58	Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study. <i>Brain Stimulation</i> , <b>2019</b> , 12, 981-991	5.1	26

57	A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. <i>NeuroImage: Clinical</i> , <b>2019</b> , 22, 101739	5.3	20
56	Neural and functional correlates of impaired reading ability in schizophrenia. <i>Scientific Reports</i> , <b>2019</b> , 9, 16022	4.9	4
55	N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia. <i>Schizophrenia Research</i> , <b>2019</b> , 207, 70-79	3.6	21
54	Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. <i>Molecular Psychiatry</i> , <b>2018</b> , 23, 1764-1772	15.1	145
53	Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2018</b> , 3, 581-590	3.4	12
52	Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. <i>Schizophrenia Research</i> , <b>2018</b> , 191, 70-79	3.6	61
51	Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia. <i>Schizophrenia Research</i> , <b>2018</b> , 191, 140-147	3.6	21
50	Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia. <i>Schizophrenia Research</i> , <b>2018</b> , 191, 51-60	3.6	44
49	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia. <i>Neuropsychopharmacology</i> , <b>2018</b> , 43, 1317-1323	8.7	52
48	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 11-19	14.5	60
47	A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia. <i>Schizophrenia Research</i> , <b>2018</b> , 191, 10-17	3.6	20
46	Neural mechanisms of mismatch negativity dysfunction in schizophrenia. <i>Molecular Psychiatry</i> , <b>2017</b> , 22, 1585-1593	15.1	57
45	Managing Negative Symptoms of Schizophrenia: How Far Have We Come?. <i>CNS Drugs</i> , <b>2017</b> , 31, 373-388	6.7	27
44	Neurophysiological Effects of Bitopertin in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 447-451	1.7	27
43	Sleep disturbances in individuals at clinical high risk for psychosis. <i>Psychiatry Research</i> , <b>2017</b> , 249, 240-243	3.9	35
42	Neural mechanisms of mismatch negativity (MMN) dysfunction in schizophrenia. <i>International Journal of Psychophysiology</i> , <b>2016</b> , 108, 37	2.9	3
41	A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 799-806	4.6	13
40	Dr Kantrowitz and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e1008	4.6	

39	Dr Kantrowitz and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e1353	4.6	
38	d-Cycloserine, an NMDA Glutamate Receptor Glycine Site Partial Agonist, Induces Acute Increases in Brain Glutamate Plus Glutamine and GABA Comparable to Ketamine. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 1241-1242	11.9	11
37	Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. <i>Brain</i> , <b>2016</b> , 139, 3281-3295	11.2	62
36	A Phase II study of a histamine H <sub>1</sub> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. <i>Schizophrenia Research</i> , <b>2015</b> , 164, 136-42	3.6	44
35	D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. <i>Lancet Psychiatry</i> , <b>2015</b> , 2, 403-412	23.3	101
34	Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia. <i>Journal of Neuroscience</i> , <b>2015</b> , 35, 14909-21	6.6	55
33	Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, 737-8	4.6	45
32	Auditory tasks for assessment of sensory function and affective prosody in schizophrenia. <i>Comprehensive Psychiatry</i> , <b>2014</b> , 55, 1862-74	7.3	12
31	Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. <i>Molecular Psychiatry</i> , <b>2014</b> , 19, 20-9	15.1	157
30	The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder. <i>Psychological Medicine</i> , <b>2014</b> , 44, 25-36	6.9	35
29	Amusia and protolanguage impairments in schizophrenia. <i>Psychological Medicine</i> , <b>2014</b> , 44, 2739-48	6.9	19
28	Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. <i>Schizophrenia Research</i> , <b>2014</b> , 152, 325-32	3.6	120
27	Reduction in tonal discriminations predicts receptive emotion processing deficits in schizophrenia and schizoaffective disorder. <i>Schizophrenia Bulletin</i> , <b>2013</b> , 39, 86-93	1.3	52
26	Lurasidone for schizophrenia: what's different?. <i>Expert Review of Neurotherapeutics</i> , <b>2012</b> , 12, 265-73	4.3	10
25	The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions. <i>Schizophrenia Research</i> , <b>2012</b> , 141, e1-e24	3.6	6
24	Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition. <i>American Journal of Psychiatry</i> , <b>2012</b> , 169, 424-32	11.9	77
23	Glutamatergic transmission in schizophrenia: from basic research to clinical practice. <i>Current Opinion in Psychiatry</i> , <b>2012</b> , 25, 96-102	4.9	121
22	Schizoaffective disorder: a review of current research themes and pharmacological management. <i>CNS Drugs</i> , <b>2011</b> , 25, 317-31	6.7	18

21	The importance of a good night's sleep: an open-label trial of the sodium salt of gamma-hydroxybutyric acid in insomnia associated with schizophrenia. <i>Schizophrenia Research</i> , <b>2010</b> , 120, 225-6	3.6	15
20	High dose D-serine in the treatment of schizophrenia. <i>Schizophrenia Research</i> , <b>2010</b> , 121, 125-30	3.6	175
19	N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. <i>Brain Research Bulletin</i> , <b>2010</b> , 83, 108-21	3.9	294
18	Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. <i>Clinical Schizophrenia and Related Psychoses</i> , <b>2010</b> , 4, 189-200	1.6	81
17	Seeing the world dimly: the impact of early visual deficits on visual experience in schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 1085-94	1.3	61
16	A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia. <i>Clinical Therapeutics</i> , <b>2009</b> , 31 Pt 1, 1360-73	3.5	12
15	Adolescent cannabis use, psychosis and catechol-O-methyltransferase genotype in African Americans and Caucasians. <i>Psychiatric Quarterly</i> , <b>2009</b> , 80, 213-8	4.1	29
14	It's all in the cards: effect of stimulus manipulation on Wisconsin Card Sorting Test performance in schizophrenia. <i>Psychiatry Research</i> , <b>2009</b> , 168, 198-204	9.9	12
13	GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications. <i>CNS Drugs</i> , <b>2009</b> , 23, 681-91	6.7	50
12	Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. <i>Expert Review of Neurotherapeutics</i> , <b>2009</b> , 9, 1045-58	4.3	21
11	Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia <b>2009</b> , 39-89		5
10	Risk of psychosis exacerbation by tricyclic antidepressants in unipolar Major Depressive Disorder with psychotic features. <i>Journal of Affective Disorders</i> , <b>2008</b> , 106, 279-84	6.6	12
9	Olanzapine: review of safety 2008. <i>Expert Opinion on Drug Safety</i> , <b>2008</b> , 7, 761-9	4.1	51
8	Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. <i>Expert Review of Neurotherapeutics</i> , <b>2008</b> , 8, 1079-93	4.3	36
7	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , <b>2008</b> , 2, 261-71	4.9	12
6	Elevated plasma dopamine metabolites in cannabis psychosis. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1615-6	11.9	12
5	Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 525-6	1.7	12
4	Three cases of risperidone-induced enuresis. <i>Schizophrenia Research</i> , <b>2006</b> , 84, 174-5	3.6	26

3	Synaptic depolarizing GABA Response in adults is excitatory and proconvulsive when GABAB receptors are blocked. <i>Journal of Neurophysiology</i> , <b>2005</b> , 93, 2656-67	3.2	22
2	Resolution of transient ischemic attacks and aortic arch thrombi on anticoagulant therapy. <i>European Neurology</i> , <b>2000</b> , 43, 184-5	2.1	
1	Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglometad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacobOLD in Healthy Volunteers		4